Gilead rises after earnings, revenue beat
Gilead rose in after-hours trading after it reported earnings and revenue results that exceeded Wall Street expectations.
The drugmaker reported adjusted earnings per share of $2.01, flat year over year but more than the $1.96 analysts polled by FactSet were expecting. It also reported revenue of $7.1 billion, more than the $6.9 billion analysts expected.
The company recently won approval for a twice-yearly HIV prevention shot, a tailwind for the company, which has seen its sales decline since its patent for a pill version of the drug expired in 2020.